Navigation Links
Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
Date:8/31/2009

l was able to provide a thorough review of the advancements in science that have brought about today's second generation cell therapies and to put our product, C-Cure, into context. We believe C-Cure has tremendous potential to realise the promise of regenerative therapies in heart failure and look forward to the results of our pivotal trial."

C-Cure draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient's own bone marrow cells and through a proprietary culturing technology, gives rise to 'cardiopoietic' cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

    For more inform
'/>"/>
SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... , Sept. 30, 2014 Report Details ... with highest potential revenues Do you want to ... gives you revenue predictions for those biological drugs ... therapies you find financial data, R&D trends, opportunities ... get sales forecasts to 2024 at overall world ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration ... budgets and increased acceptance of new filtration technologies in ... industries are also catalyzing the growth of laboratory filtration ... to grow at a strong CAGR during the forecast ... $2,532.6 million by 2019. The market is mainly driven ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... team of University of Washington undergraduate students was among ... one of the Bill & Melinda Gates Foundation,s $100,000 ... fifth round of Grand Challenges Explorations, an initiative to ... unproven ways to improve health in developing countries. To ...
... release is available in Spanish . , U.S. ... ways to improve soil on degraded land so it can ... with USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian ... constructed or replacement subsoils and topsoils to build better and ...
... Albert Einstein College of Medicine of Yeshiva University researcher ... Honor in Basic Science from the American Cancer Society ... role the tumor microenvironment plays in modulating cancer behavior, ... cells called macrophages play both in normal development and ...
Cached Biology News:Undergraduates' low-cost ultrasound system wins Gates Foundation grant 2Undergraduates' low-cost ultrasound system wins Gates Foundation grant 3Improving soil for better lawns and gardens 2Einstein researcher receives American Cancer Society Medal of Honor 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: